CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- 4 Open-market sale Chief Financial Officer sold 4,398 shares at $13.62 ($59,901)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Financial Officer acquired 68,750 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 57,500 shares (grant or award)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Open-market sale Chief Scientific Officer sold 416 shares at $12.03 ($5,004)
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Planned sale Chief Scientific Officer sold 4,000 shares at $12.30 ($49,200)
- 144 Insider Sale of Securities
- 8-K Event Results of operations · Regulation FD disclosure · Other events
- 4 Grant or award Chief Financial Officer acquired 27 shares (grant or award)
- 4 Open-market sale President and CEO sold 9,922 shares at $10.01 ($99,319)
- 4 Planned sale Chief Scientific Officer sold 1,345 shares at $10.01 ($13,463)
- 4 Open-market sale Chief Legal Officer sold 3,480 shares at $9.67 ($33,652)
- 4 Open-market sale Chief Medical Officer sold 4,632 shares at $9.67 ($44,791)
Page 4 of 24 · 471 filings